Allergic and autoimmune diseases are forms of immune hypersensitivity that increasingly
cause chronic ill health. Most current therapies treat symptoms rather than addressing …

Myasthenia gravis (MG) is the most common autoimmune disorder affecting the
neuromuscular junction, characterized by skeletal muscle weakness and fatigability. It is …

Myasthenia gravis (MG) is an autoimmune disease associated with the production of
autoantibodies against 1) the skeletal muscle acetylcholine receptor; 2) muscle-specific …

Our understanding of the basic mechanisms controlling the generation of productive
immunity continues to evolve at a great pace. Models of how the immune response may be …

This review article summarises the initial preclinical studies as well as the different stages of
clinical trials in multiple sclerosis (MS) with Copolymer 1 (Cop 1), recently denoted …

Myasthenia gravis (MG) and experimental autoimmune MG are T cell-dependent antibody-
mediated autoimmune diseases. A dual altered peptide ligand (APL), composed of the …

Autoimmune diseases affect approximately 1 in 21 persons in the United States. Treatment
often requires long-term cytotoxic therapy. How and why these deleterious diseases occur is …

Similarly to prophylactic vaccines whose purpose is to prevent infectious diseases,
therapeutic vaccines against autoimmune diseases are based on their similarity to the …

Myasthenia Gravis (MG)–an autoimmune neuromuscular disease–is known by the
production of autoantibodies against components of the neuromuscular junction mainly to …

Myasthenia gravis (MG) and experimental autoimmune MG (EAMG) are T-cell regulated,
antibody-mediated diseases. Peptides p195–212 and p259–271 of the human acetylcholine …